26 closest matches · ranked by relevance
Smallpox
Primary: Number of Participants Reporting Adverse Events of Severe Intensity Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine — 2; 4; 3; 4 Participants
Vaccination
Primary: ELISA Seropositivity Rate — 40.9; 100.0 percentage of subjects
Smallpox
Primary: Cutaneous Take Reaction — 81; 41 participants
Smallpox
Primary: Geometric Mean Titer (GMT) Based on Vaccinia-specific Individual Peak Plaque Reduction Neutralization Titers (PRNT) Following 2 Doses of IMVAMUNE® Lyophilized Versus…
Smallpox
Primary: Number of Participants Reporting Moderate or Greater Solicited Local Reactions — 3; 0; 1; 6 Participants
HIV Infections
Primary: Serious Adverse Events — 0; 17; 0; 6 Participants
Smallpox
Primary: Time to Seroconversion After One Vaccination Using Bavarian Nordic's (BN) Enzyme Linked Immunosorbent Assay (ELISA) in the Intent-to-Treat (ITT) Population — 14; 14 days
Smallpox
Primary: The Neutralizing Antibody Response Titers Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine — 77; 112; 76; 91 PRNT50 Titers
Smallpox
Primary: Vaccinia-Specific Neutralizing Antibodies Measured by Plaque Reduction Neutralization Test (PRNT) — 252.7; 269.9; 242.0 Titer
Atopic Dermatitis
Primary: Percentage of Participants With Seroconversion by ELISA — 98.5; 97.3 percentage of subjects
Smallpox
Primary: Related Serious Adverse Events — 0; 0 Participants
Smallpox
Primary: PRNT GMT — 110.7; 100.5; 117.2; 1.0 Titer
Orthopoxviral Disease · Smallpox · Monkey Pox
Primary: Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: t½ — 27.446; 28.180 hours — p=0.4591
Smallpox
Primary: Geometric Mean Titer (GMT) of Bavarian Nordic's (BN) Plaque Reduction Neutralizing Antibody Titer (PRNT) Assay in Groups A and B — 10.8; 30.2 titer
Smallpox
Primary: Percentage of Participants With Seroconversion by ELISA — 98.9; 82.2; 3.4; 95.5 percentage of subjects
Smallpox
Primary: ELISA GMT — 875.1; 1099.6 Titer
Smallpox Vaccine Adverse Reaction
Primary: Percent of Participants With Adverse Events Related to ACAM2000 Vaccine Administration — 52; 8; 4 percentage of participants
18-42 Year Old Healthy Vaccinia-naïve Subjects
Primary: Plaque Reduction Neutralization Test (PRNT) Geometric Mean Titer (GMT) at the Peak Visits — 153.5; 79.3 Titer
Smallpox
Primary: Geometric Mean Peak Plaque Reduction Neutralization Titer (PRNT) After Second Vaccination — 138.0; 55.1; 75.9; 103.5 titers
Monkeypox
Primary: Vaccinia Virus Specific Plaque Reduction Neutralization Test (PRNT) Geometric Mean Titer (GMT) at Day 43 — 203.2; 113.2; 288.9 titer — p=0.045
Monkeypox
Primary: Time to Lesion Resolution — 7; 8 Days
Smallpox
Primary: Number of Participants With SAEs — 0; 0; 2; 0 Participants
Monkeypox
Primary: Vaccinia Virus Specific Plaque Reduction Neutralization Test (PRNT) Geometric Mean Titer (GMT) — 470.3; 295.7; 293.2 titer — p=<0.001
Smallpox Vaccine Adverse Reaction
Primary: Number of Vaccinated Participants With Adverse Events (AEs) Including Serious Adverse Events (SAEs) — 1420 Participants
Ebola Virus
Primary: Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity — 17.2; 21.9; 29.7; 45.3 Percentage of Participants
Smallpox
Primary: To Determine the Number of Participants With Adverse Events — 134; 30 Participants